87 related articles for article (PubMed ID: 11642327)
1. N-Acetyltransferase 2 genotype correlates with sulfasalazine pharmacokinetics after multiple dosing in healthy Japanese subjects.
Kita T; Sakaeda T; Adachi S; Sakai T; Aoyama N; Hatanaka H; Kasuga M; Okumura K
Biol Pharm Bull; 2001 Oct; 24(10):1176-80. PubMed ID: 11642327
[TBL] [Abstract][Full Text] [Related]
2. N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.
Kumagai S; Komada F; Kita T; Morinobu A; Ozaki S; Ishida H; Sano H; Matsubara T; Okumura K
Pharm Res; 2004 Feb; 21(2):324-9. PubMed ID: 15032315
[TBL] [Abstract][Full Text] [Related]
3. N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events.
Tanigawara Y; Kita T; Aoyama N; Gobara M; Komada F; Sakai T; Kasuga M; Hatanaka H; Sakaeda T; Okumura K
Biol Pharm Bull; 2002 Aug; 25(8):1058-62. PubMed ID: 12186410
[TBL] [Abstract][Full Text] [Related]
4. Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population.
Ma JJ; Liu CG; Li JH; Cao XM; Sun SL; Yao X
Clin Chim Acta; 2009 Sep; 407(1-2):30-5. PubMed ID: 19560446
[TBL] [Abstract][Full Text] [Related]
5. Kinetic phenotypic diagnosis of N-acetylation polymorphism in patients based on ratio of urinary metabolites of salicylazosulfapyridine.
Yokogawa K; Nakaharu T; Ishizaki J; Ozaki E; Takeda Y; Mabuchi H; Matsushita R; Kimura K; Nakashima E; Ichimura F; Miyamoto K
Int J Pharm; 2001 Oct; 229(1-2):183-91. PubMed ID: 11604271
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.
Yamasaki Y; Ieiri I; Kusuhara H; Sasaki T; Kimura M; Tabuchi H; Ando Y; Irie S; Ware J; Nakai Y; Higuchi S; Sugiyama Y
Clin Pharmacol Ther; 2008 Jul; 84(1):95-103. PubMed ID: 18167504
[TBL] [Abstract][Full Text] [Related]
7. N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.
Chen M; Xia B; Chen B; Guo Q; Li J; Ye M; Hu Z
Can J Gastroenterol; 2007 Mar; 21(3):155-8. PubMed ID: 17377643
[TBL] [Abstract][Full Text] [Related]
8. Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics.
Kuhn UD; Anschütz M; Schmücker K; Schug BS; Hippius M; Blume HH
Int J Clin Pharmacol Ther; 2010 Jan; 48(1):1-10. PubMed ID: 20040334
[TBL] [Abstract][Full Text] [Related]
9. N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients.
Kita T; Tanigawara Y; Chikazawa S; Hatanaka H; Sakaeda T; Komada F; Iwakawa S; Okumura K
Biol Pharm Bull; 2001 May; 24(5):544-9. PubMed ID: 11379777
[TBL] [Abstract][Full Text] [Related]
10. Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.
Clarke DF; George D; Milsap RL; Pogonowska-Wala E; Owerbach J; Lebenthal E; Jusko WJ
Pediatr Pharmacol (New York); 1982; 2(4):323-33. PubMed ID: 6152489
[TBL] [Abstract][Full Text] [Related]
11. Studies on N-Acetyltransferase (NAT2) Genotype Relationships in Emiratis: Confirmation of the Existence of Phenotype Variation among Slow Acetylators.
Al-Ahmad MM; Amir N; Dhanasekaran S; John A; Abdulrazzaq YM; Ali BR; Bastaki S
Ann Hum Genet; 2017 Sep; 81(5):190-196. PubMed ID: 28653770
[TBL] [Abstract][Full Text] [Related]
12. Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.
Bates TR; Blumenthal HP; Pieniaszek HJ
Clin Pharmacol Ther; 1977 Dec; 22(6):917-27. PubMed ID: 21768
[TBL] [Abstract][Full Text] [Related]
13. Toxicokinetics of sulfasalazine (salicylazosulfapyridine) and its metabolites in B6C3F1 mice.
Zheng W; Winter SM; Mayersohn M; Bishop JB; Sipes IG
Drug Metab Dispos; 1993; 21(6):1091-7. PubMed ID: 7905389
[TBL] [Abstract][Full Text] [Related]
14. Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism.
Okumura K; Kita T; Chikazawa S; Komada F; Iwakawa S; Tanigawara Y
Clin Pharmacol Ther; 1997 May; 61(5):509-17. PubMed ID: 9164413
[TBL] [Abstract][Full Text] [Related]
15. N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis.
Ricart E; Taylor WR; Loftus EV; O'Kane D; Weinshilboum RM; Tremaine WJ; Harmsen WS; Zinsmeister AR; Sandborn WJ
Am J Gastroenterol; 2002 Jul; 97(7):1763-8. PubMed ID: 12135032
[TBL] [Abstract][Full Text] [Related]
16. The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine.
Awni WM; Braeckman RA; Locke CS; Dubé LM; Granneman GR
Clin Pharmacokinet; 1995; 29 Suppl 2():98-104. PubMed ID: 8620678
[TBL] [Abstract][Full Text] [Related]
17. Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine.
Ohtani T; Hiroi A; Sakurane M; Furukawa F
Br J Dermatol; 2003 May; 148(5):1035-9. PubMed ID: 12786839
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetics of salazosulfapyridine in a hemodialysis patient].
Akiyama Y; Fujimaki T; Sakurai Y
Ryumachi; 2003 Jun; 43(3):569-76. PubMed ID: 12910967
[TBL] [Abstract][Full Text] [Related]
19. Mesalazine pharmacokinetics and NAT2 phenotype.
Lück H; Kinzig M; Jetter A; Fuhr U; Sörgel F
Eur J Clin Pharmacol; 2009 Jan; 65(1):47-54. PubMed ID: 18704388
[TBL] [Abstract][Full Text] [Related]
20. Increased frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer.
Gil JP; Lechner MC
Carcinogenesis; 1998 Jan; 19(1):37-41. PubMed ID: 9472690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
